Roivant Sciences rises after positive trial data for muscle-and-skin disease drug

Roivant Sciences

17/09/2025 14:51

Updates

** Shares of drugmaker Roivant Sciences ROIV.O rise 12.7% to $15.98

** Roivant and partner Priovant say their once-daily pill, brepocitinib, helped adults with dermatomyositis do better across multiple measures in a year-long late-stage study

** Dermatomyositis is a rare disease that weakens muscles and causes painful skin rashes

** In the 52-week trial, patients taking the 30mg dose showed better overall improvement than those on a placebo, starting as early as week four

** Safety was in line with earlier studies, companies say

** Roivant and Priovant say they plan to file for U.S. approval in the first half of 2026

** Including session's move, ROIV shares up ~33% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))